Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium-67 is a radioactive isotope of gallium, primarily used in nuclear medicine as a diagnostic **radiopharmaceutical** in the form of gallium-67 citrate. It is cyclotron-produced and has a half-life of 78.3 hours. When injected intravenously as gallium-67 citrate, it binds in the bloodstream to transferrin, lactoferrin, and other proteins, mimicking the behavior of ferric iron. This leads to its accumulation in tumor tissues, sites of infection, and inflammation by mechanisms such as increased blood flow, metabolic activity, and iron transport protein expression in these regions. Imaging is performed by detecting gamma radiation from the isotope using SPECT. Its main indications are the detection and evaluation of lymphoma (especially Hodgkin’s), lung cancer, and sites of infection or inflammation (e.g., fever of unknown origin, sarcoidosis, osteomyelitis)[1][2][4][7][8][9]. Unlike gallium-68, which is used in PET, gallium-67 is used for SPECT/gamma camera imaging[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallium-67.